CN112426369A - Cannabidiol cream composition and preparation method and application thereof - Google Patents
Cannabidiol cream composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN112426369A CN112426369A CN202011437715.5A CN202011437715A CN112426369A CN 112426369 A CN112426369 A CN 112426369A CN 202011437715 A CN202011437715 A CN 202011437715A CN 112426369 A CN112426369 A CN 112426369A
- Authority
- CN
- China
- Prior art keywords
- cannabidiol
- phase
- cream composition
- essential oil
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims abstract description 87
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229950011318 cannabidiol Drugs 0.000 title claims abstract description 85
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims abstract description 85
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims abstract description 85
- 239000006071 cream Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000000341 volatile oil Substances 0.000 claims abstract description 28
- 239000003921 oil Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 19
- 239000002562 thickening agent Substances 0.000 claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 18
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 18
- 239000003906 humectant Substances 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 16
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 14
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000002776 aggregation Effects 0.000 claims abstract description 7
- 238000004220 aggregation Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000001556 precipitation Methods 0.000 claims abstract description 6
- 238000003860 storage Methods 0.000 claims abstract description 5
- -1 polyethylene Polymers 0.000 claims description 27
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 125000005456 glyceride group Chemical group 0.000 claims description 12
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- 229940114926 stearate Drugs 0.000 claims description 12
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 10
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000010008 shearing Methods 0.000 claims description 8
- 229940008099 dimethicone Drugs 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- 230000008439 repair process Effects 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960002216 methylparaben Drugs 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 4
- 239000008236 heating water Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 3
- 240000002319 Citrus sinensis Species 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 229940092738 beeswax Drugs 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 239000001102 lavandula vera Substances 0.000 claims description 3
- 235000018219 lavender Nutrition 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- 229940012831 stearyl alcohol Drugs 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a cannabidiol cream composition and a preparation method and application thereof, and the cannabidiol cream composition comprises the following components in percentage by weight: 0.5-5% of cannabidiol, 5-40% of an oil phase solvent, 5-30% of an emulsifier, 5-15% of a humectant, 5-15% of a thickener, 0.2-1.5% of an antioxidant, 0.2-1.5% of a bacteriostatic agent, 0.05-0.3% of a pH regulator, 0.05-0.3% of essential oil and 35-70% of water; preparation: mixing an oil phase solvent, an emulsifier, a thickening agent, an antioxidant and a bacteriostatic agent to prepare an oil phase; using water as a water phase; adding cannabidiol into humectant to prepare medicine-containing phase; adding the oil phase into the water phase, mixing, adding the medicine-containing phase, and mixing; the cream is prepared by adding the rest components, has good storage stability, has no phenomena of layering, aggregation and precipitation, can be stored for a long time, and can fully utilize the functions of the cream in the aspects of treating eczema, tightening skin, resisting oxidation, repairing, delaying senility and the like.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a cannabidiol cream composition as well as a preparation method and application thereof.
Background
The skin is the first physiological defense line and the largest organ of the human body, is wrapped on the surface of the human body and directly contacts with the external environment, and has the functions of protecting, excreting, regulating body temperature, feeling external stimulation and the like. Thus, when the physiological function of the skin is impaired, skin diseases are caused. Eczema is the most common allergic skin disease, is characterized by redness, edema, pruritus and dryness, can be accompanied by scabbing, peeling, blistering, cracking, bleeding or blood seepage, has irregular course and is easy to repeatedly attack. The key points of treating eczema are sterilization, itching relieving, inflammation diminishing and moisture retention. At present, the eczema is mainly treated clinically by glucocorticoid inhibitors, tar preparations, immunomodulators or external antibiotic preparations, but the local adverse reactions such as drug resistance, skin atrophy, telangiectasis, pigmentation and the like are easy to generate when the hormones and the antibiotics are clinically used for a long time.
Due to the damage of daily ultraviolet rays and pollutants in the air and the long-term accompanying work and living states of electronic products, a plurality of skin sub-health problems such as dark, dark and yellow skin, lack of luster, pigmentation, inflammatory reaction, wrinkle increase, loose skin, rough skin and the like of modern cities with high living pressure and fast pace are easily caused.
Cannabidiol is a non-toxic and non-addictive component in cannabis, can prevent the adverse effect of tetrahydrocannabinol on human nervous system, and is one of the most important physiological active ingredients in cannabis phenolic substances. Cannabidiol is applied to the field of cosmetics, can mainly repair nerve fibers of a human body, has pharmacological activities of antianxiety, sedation, anti-inflammation, immunoregulation, antioxidation, ultraviolet resistance and the like, can relieve skin, maintain the optimal state of the skin, repair skin barriers and resist aging after being taken into the human body through the skin, and thus improves the skin quality from inside to outside.
Meanwhile, multiple researches show that the cannabidiol generates anti-inflammatory activity by regulating the generation of cytokines and can be locally applied to treat allergic skin diseases such as eczema.
However, cannabidiol is a fat-soluble and water-insoluble substance, and is directly added into cosmetics in a water-soluble manner, so that the bioavailability is extremely low, the transdermal absorption is poor, and the requirements of people on the cannabidiol product for treating eczema, resisting aging, tightening skin and the like are difficult to meet.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide an improved cannabidiol cream composition which has good storage stability and no layering, aggregation and precipitation phenomena, so that the cannabidiol cream composition can be stored for a long time and can fully utilize the effects of the cannabidiol cream composition on treating eczema, tightening skin, resisting oxidation, repairing, delaying senescence and the like.
The invention also provides a preparation method of the cannabidiol cream composition.
The invention also provides application of the cannabidiol cream composition in cosmetics or medicines for treating eczema, tightening skin, resisting oxidation, repairing and delaying senescence.
In order to achieve the purpose, the invention adopts a technical scheme that:
the cannabidiol cream composition comprises the following components in percentage by weight: 0.5-5.0% of cannabidiol, 5.0-40.0% of oil phase solvent, 5.0-30.0% of emulsifier, 5.0-15.0% of humectant, 5.0-15.0% of thickener, 0.2-1.5% of antioxidant, 0.2-1.5% of bacteriostatic agent, 0.05-0.3% of pH regulator, 0.05-0.3% of essential oil and 35.0-70.0% of water.
According to some preferred aspects of the present invention, the cannabidiol cream composition comprises the following components in weight percent: 0.5-5.0% of cannabidiol, 5.0-20.0% of oil phase solvent, 5.0-20.0% of emulsifier, 5.0-10.0% of humectant, 5.0-13.0% of thickener, 0.3-1.0% of antioxidant, 0.3-1.0% of bacteriostatic agent, 0.1-0.3% of pH regulator, 0.1-0.3% of essential oil and 45.0-70.0% of water.
According to some preferred and specific aspects of the present invention, the emulsifier is a combination of one or more selected from the group consisting of polyethylene glycol-7-stearate, oleoyl polyoxyethylene glyceride, polysorbate 80, and polyoxyethylene 20 oleyl ether.
According to a preferred aspect of the invention, the emulsifier is composed of polyethylene glycol-7-stearate and oleoyl polyoxyethylene glyceride, and the feeding mass ratio of the polyethylene glycol-7-stearate to the oleoyl polyoxyethylene glyceride is 1-8: 1.
According to some preferred and specific aspects of the present invention, the thickener is one or a combination of more selected from the group consisting of cetyl alcohol, stearyl alcohol, glyceryl monostearate and dimethicone.
According to some preferred and specific aspects of the present invention, the thickener is composed of glyceryl monostearate and dimethicone, and the feeding mass ratio of the glyceryl monostearate to the dimethicone is 1-5: 1.
According to some preferred aspects of the invention, the cannabidiol cream composition has a pH value of 5-6.
According to some specific and preferred aspects of the present invention, the oil phase solvent is a combination of one or more selected from medium chain triglycerides, diethylene glycol monoethyl ether, beeswax, stearic acid and liquid paraffin.
According to some specific and preferred aspects of the present invention, the humectant is a combination of one or more selected from the group consisting of glycerin, propylene glycol, an amino acid, and urea.
According to some specific and preferred aspects of the present invention, the antioxidant is one or a combination of more selected from the group consisting of tocopherol, dibutylhydroxytoluene, and butylhydroxyanisole.
According to some specific and preferred aspects of the present invention, the bacteriostatic agent is one or more selected from phenoxyethanol, methyl paraben and ethyl paraben.
According to some specific and preferred aspects of the present invention, the selected pH adjusting agent is one or a combination of more selected from triethanolamine, disodium hydrogen phosphate and sodium hydrogen phosphate.
According to some specific and preferred aspects of the present invention, the essential oil is one or more selected from the group consisting of sweet orange essential oil, lemon essential oil, lavender essential oil and rosemary essential oil.
According to the present invention, the cannabidiol cream composition exhibits, after storage for at least one month at a temperature of 40 ± 2 ℃ and a relative humidity (hereinafter, RH) of 75 ± 5.0%: uniform and fine, without layering, aggregation or precipitation.
The invention provides another technical scheme that: a preparation method of the cannabidiol cream composition comprises the following steps:
step 1: preparing a phase 1-oil phase, mixing an oil phase solvent, an emulsifier, a thickening agent, an antioxidant and a bacteriostatic agent, and heating to 60-80 ℃;
step 2: heating water in the formula to 60-80 ℃ to be used as a phase 2-water phase;
and step 3: preparing a phase 3-drug-containing phase, adding cannabidiol into a humectant, and heating to 60-80 ℃ until the cannabidiol is dissolved and clarified;
and 4, step 4: adding the phase 1-oil phase into the phase 2-water phase under the condition of stirring, and shearing and emulsifying at the temperature of 60-80 ℃ and the rpm of 1000-2000; adding the phase 3-containing medicine phase, and continuously maintaining the temperature of 60-80 ℃ for shearing and emulsification;
and 5: and (3) cooling at 25 +/-5 ℃, adding essential oil, and adjusting the pH value to 5-6 by using a pH regulator to prepare the cannabidiol cream composition.
The invention provides another technical scheme that: the cannabidiol cream composition is applied to cosmetics or medicines for treating eczema, tightening skin, resisting oxidation, repairing and delaying senescence.
Due to the application of the technical scheme, compared with the prior art, the invention has the following advantages:
the invention provides a cannabidiol cream compound composition based on the problems that cannabidiol is fat-soluble and insoluble in water in the prior art, is directly added into cosmetics in a water-soluble way, has extremely low bioavailability and poor transdermal absorption, and the cannabidiol in the composition exists in a final product in a cream form, has good stability, and still shows after being stored for at least one month under the condition of 40 +/-2 ℃/RH75 +/-5.0 percent: the cannabidiol cream is uniform and fine, has no layering, aggregation or precipitation phenomena, solves the problems of extremely low bioavailability and poor transdermal absorption when cannabidiol is used in cosmetics in the prior art, greatly prolongs the storage period of the cannabidiol cream, and simultaneously can better play the roles of the cannabidiol cream in treating eczema, tightening skin, resisting oxidation, repairing, delaying senility and the like.
Detailed Description
For a further understanding of the invention, reference will now be made to the preferred embodiments of the present invention by way of example, and it is to be understood that the description is intended to further illustrate features and advantages of the present invention, and not to limit the scope of the claims.
The invention provides a cannabidiol cream composition which comprises the following components in percentage by weight: 0.5-5.0% of cannabidiol, 5.0-40.0% of oil phase solvent, 5.0-30.0% of emulsifier, 5.0-15.0% of humectant, 5.0-15.0% of thickener, 0.2-1.5% of antioxidant, 0.2-1.5% of bacteriostatic agent, 0.05-0.3% of pH regulator, 0.05-0.3% of essential oil and 35.0-70.0% of water.
Cannabidiol, chinese name: 2- [ (1R,6R) -3-methyl-6- (1-methylvinyl) -2-cyclohexen-1-yl]-5-pentyl-1, 3-benzenediol of the formula C21H30O2Molecular weight 314.46, CAS registry number 13956-29-1. Cannabidiol is a white to light yellow crystalline solid, is insoluble in water, is easily soluble in organic solvents such as ethanol, methanol, ether, oil and the like, and has a molecular structural formula as follows:
preferably, the cannabidiol cream composition comprises the following components in percentage by weight: 0.5-5.0% of cannabidiol, 5.0-20.0% of oil phase solvent, 5.0-20.0% of emulsifier, 5.0-10.0% of humectant, 5.0-13.0% of thickener, 0.3-1.0% of antioxidant, 0.3-1.0% of bacteriostatic agent, 0.1-0.3% of pH regulator, 0.1-0.3% of essential oil and 45.0-70.0% of water.
According to the present invention, the emulsifier of the present invention may be selected from the conventional emulsifier types, but it is preferable to use a combination of one or more selected from polyethylene glycol-7-stearate, oleoyl polyoxyethylene glyceride, polysorbate 80 and polyoxyethylene 20 oleyl ether; more preferably, the feed additive is composed of polyethylene glycol-7-stearate and oleoyl polyoxyethylene glyceride, and the feeding mass ratio of the polyethylene glycol-7-stearate to the oleoyl polyoxyethylene glyceride is 1-8: 1; still further preferably, the feeding mass ratio of the polyethylene glycol-7-stearate to the oleoyl polyoxyethylene glyceride is 2-6: 1.
According to the present invention, the thickener of the present invention may be selected from the conventional thickener types in the prior art, but it is preferable to use one or a combination of more selected from the group consisting of cetyl alcohol, stearyl alcohol, glyceryl monostearate and dimethicone; more preferably, the feed additive is composed of glyceryl monostearate and dimethyl silicone oil, and the feeding mass ratio of the glyceryl monostearate to the dimethyl silicone oil is 1-5: 1.
The pH value of the cannabidiol cream composition is preferably 5-6.
Preferably, in the present invention, the oil phase solvent is a combination of one or more selected from medium chain triglycerides, diethylene glycol monoethyl ether, beeswax, stearic acid and liquid paraffin. In some preferred embodiments, the oil phase solvent is a medium chain triglyceride and/or diethylene glycol monoethyl ether.
Preferably, in the present invention, the humectant is one or a combination of more selected from glycerin, propylene glycol, amino acid and urea. In some preferred embodiments, the humectant is propylene glycol and/or glycerin.
Preferably, in the present invention, the antioxidant is one or more selected from tocopherol, butylated hydroxytoluene and butylated hydroxyanisole. In some preferred embodiments, the antioxidant is butylated hydroxytoluene and/or butylated hydroxyanisole.
Preferably, in the invention, the bacteriostatic agent is one or more of phenoxyethanol, methyl paraben and ethyl paraben. In some preferred embodiments, the bacteriostatic agent is methyl paraben and/or ethyl paraben.
Preferably, in the present invention, the selected pH adjusting agent is one or a combination of more selected from triethanolamine, disodium hydrogen phosphate and sodium hydrogen phosphate. In some preferred embodiments, the pH adjusting agent selected is triethanolamine.
Preferably, in the present invention, the essential oil is one or more selected from sweet orange essential oil, lemon essential oil, lavender essential oil and rosemary essential oil.
The present invention also provides a preferred method for preparing the cannabidiol cream composition, which comprises the following steps:
step 1: preparing a phase 1-oil phase, mixing an oil phase solvent, an emulsifier, a thickening agent, an antioxidant and a bacteriostatic agent, and heating to 60-80 ℃;
step 2: heating water in the formula to 60-80 ℃ to be used as a phase 2-water phase;
and step 3: preparing a phase 3-drug-containing phase, adding cannabidiol into a humectant, and heating to 60-80 ℃ until the cannabidiol is dissolved and clarified;
and 4, step 4: adding the phase 1-oil phase into the phase 2-water phase under the condition of stirring, and shearing and emulsifying at the temperature of 60-80 ℃ and the rpm of 1000-2000; adding the phase 3-containing medicine phase, and continuously maintaining the temperature of 60-80 ℃ for shearing and emulsification;
and 5: and (3) cooling at 25 +/-5 ℃, adding essential oil, and adjusting the pH value to 5-6 by using a pH regulator to prepare the cannabidiol cream composition.
In the present invention, the cannabidiol cream composition can exhibit, after being stored for at least one month at a temperature of 40 ± 2 ℃ and a relative humidity (hereinafter, RH) of 75 ± 5.0%: uniform and fine, without layering, aggregation or precipitation. The cannabidiol cream composition has excellent stability and dispersibility, improves the bioavailability and transdermal absorbability, can make cannabidiol enter local parts of the skin and promote the skin to absorb effective components of the cannabidiol, so that the cannabidiol can inhibit local inflammatory reaction and treat skin eczema; meanwhile, the adopted various moisturizing agents and raw materials with repair functions can improve the health state of the skin, repair skin barriers, enable the skin to have stronger resistance, tighten the skin, resist oxidation, repair and delay aging.
The above-described scheme is further illustrated below with reference to specific examples; it is to be understood that these embodiments are provided to illustrate the general principles, essential features and advantages of the present invention, and the present invention is not limited in scope by the following embodiments; the implementation conditions used in the examples can be further adjusted according to specific requirements, and the implementation conditions not indicated are generally the conditions in routine experiments.
Not specifically illustrated in the following examples, all starting materials are commercially available or prepared by methods conventional in the art.
Samples are prepared according to the following examples respectively, the stability of the samples in different examples is examined by the inventor, the samples are placed in the test condition of 40 +/-2 ℃/RH75 +/-5.0%, the samples are sampled respectively in 0 day, 1 month, 2 months and 3 months, the change condition of indexes such as characters and the like is examined, and the skin use experience of the cannabidiol cream is evaluated by the inventor through a volunteer test. Wherein cannabidiol is purchased from Shandong Tei enamel pharmaceutical Co., Ltd, medium chain triglyceride is purchased from Zhonghang pharmaceutical Co., Ltd, polyethylene glycol-7-stearate (trade name:
63) oleoyl polyoxyethylene glyceride (brand:
m1944 CS), glycerol monostearate (brand: geleolTMmono and diglycerides NF) was purchased from gale corporation.
Example 1
The present example provides a cannabidiol cream composition with the component formulations and amounts shown in table 1.
Table 1 example 1 formulation
Cannabidiol cream compositions were prepared according to the formulation composition in table 1 and the following preparation steps:
step 1: preparing phase 1-oil phase, mixing oil phase solvent, emulsifier, thickener, antioxidant and bacteriostatic agent, and heating to 70 + -5 deg.C;
step 2: heating water in the formula to 70 +/-5 ℃ to serve as a phase 2-water phase;
and step 3: preparing phase 3-drug-containing phase, adding cannabidiol into humectant, heating to 70 + -5 deg.C for dissolving and clarifying;
and 4, step 4: adding the phase 1-oil phase into the phase 2-water phase under stirring, maintaining the temperature at 70 + -5 deg.C, and shearing and emulsifying at 1500rpm for 5 min; adding the phase 3-containing medicine, continuously keeping the temperature of 60-80 ℃, and shearing and emulsifying for 10 min;
and 5: cooling at 25 +/-5 ℃, adding essential oil, adjusting the pH value to 5-6 by using triethanolamine to obtain a uniform cannabidiol cream composition, and subpackaging the uniform cream.
Example 2
The present example provides a cannabidiol cream composition with the component formulations and amounts shown in table 2.
Table 2 example 2 formulation
This example is substantially the same as example 1 except that the cannabidiol was used in an amount of 3% and the humectant propylene glycol was adjusted to 8%.
Example 3
The present example provides a cannabidiol cream composition with the component formulations and amounts shown in table 3.
Table 3 example 3 formulation
This example is essentially the same as example 1 except that the emulsifier polyethylene glycol-7-stearate was adjusted to 12%, oleoyl polyoxyethylene glyceride was adjusted to 4%, and the thickener glyceryl monostearate was adjusted to 5%.
Example 4
The present example provides a cannabidiol cream composition with the component formulations and amounts shown in table 4.
Table 4 example 4 formulation
This example is substantially the same as example 1 except that the bacteriostatic agent is methylparaben and the essential oil is orange essential oil.
Example 5
The present example provides a cannabidiol cream composition with the component formulations and amounts shown in table 5.
Table 5 example 5 formulation
This example is substantially the same as example 1, except that the ratio of the antioxidant dibutylhydroxytoluene is adjusted to 0.4%, and the ratio of the bacteriostatic agent ethylparaben is adjusted to 0.5%.
Comparative example 1
Cannabidiol cream was prepared according to the formulation composition in table 6 and the following preparation procedure as comparative example 1 for stability test and volunteer trial test.
TABLE 6 COMPARATIVE EXAMPLE 1 formulation
The preparation method is the same as example 1.
Comparative example 2
Cannabidiol cream was prepared according to the formulation composition in table 7 and the following preparation procedure as comparative example 2 for stability test and volunteer trial test.
TABLE 7 COMPARATIVE EXAMPLE 2 formulation
The preparation method is the same as example 1.
Stability test
The samples of examples 1 to 5 and comparative examples 1 to 2 were placed under test conditions of 40. + -.2 ℃ RH 75. + -. 5.0%, sampled at 1 month, 2 months and 3 months, respectively, and the changes in cream properties, appearance and the like were observed, and the results are shown in Table 8.
TABLE 8 results of stability test of examples 1 to 5 and comparative examples 1 to 2
And (4) analyzing results: cannabidiol cream in homogeneous form has good stability in the final product. Storing for more than 1 month under the test condition of accelerating 40 plus or minus 2 ℃/RH75 plus or minus 5.0 percent, and keeping the consistency to be moderate and white; no demixing, aggregation or educts are generated, which shows that the cannabidiol cream has good stability.
Trial test of volunteers
In order to confirm the experience of the present invention, the cannabidiol creams of examples 1-5 and the creams of comparative examples 1-2 were used for trial use among the employees of the company and the volunteers of the relatives, respectively.
Age of volunteer: 20-50 years old
Volunteer skin type: oily, dry, sensitive skin
75 volunteers
Evaluation principle: the product has the advantages of good wettability, fineness, no greasy feeling, no irritation, and good use feeling.
TABLE 9 Experimental feedback of experience from volunteers of examples 1-5 and comparative examples 1-2
And (4) analyzing results: the cannabidiol cream prepared by the invention has good use experience in volunteer people, and has the advantages of infiltration, fineness, no greasy feeling and no irritation.
The above embodiments are merely illustrative of the technical ideas and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All equivalent changes and modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
Claims (10)
1. The cannabidiol cream composition is characterized by comprising the following components in percentage by weight: 0.5-5.0% of cannabidiol, 5.0-40.0% of oil phase solvent, 5.0-30.0% of emulsifier, 5.0-15.0% of humectant, 5.0-15.0% of thickener, 0.2-1.5% of antioxidant, 0.2-1.5% of bacteriostatic agent, 0.05-0.3% of pH regulator, 0.05-0.3% of essential oil and 35.0-70.0% of water.
2. A cannabidiol cream composition according to claim 1, wherein the cannabidiol cream composition comprises in weight percent: 0.5-5.0% of cannabidiol, 5.0-20.0% of oil phase solvent, 5.0-20.0% of emulsifier, 5.0-10.0% of humectant, 5.0-13.0% of thickener, 0.3-1.0% of antioxidant, 0.3-1.0% of bacteriostatic agent, 0.1-0.3% of pH regulator, 0.1-0.3% of essential oil and 45.0-70.0% of water.
3. A cannabidiol cream composition according to claim 1 or 2, characterised in that the emulsifier is a combination of one or more selected from the group consisting of polyethylene glycol-7-stearate, oleoyl polyoxyethylene glyceride, polysorbate 80 and polyoxyethylene 20 oleyl ether, and the thickener is a combination of one or more selected from the group consisting of cetyl alcohol, stearyl alcohol, glyceryl monostearate and dimethicone.
4. A cannabidiol cream composition according to claim 3, wherein the emulsifier comprises polyethylene glycol-7-stearate and oleoyl polyoxyethylene glyceride, and the mass ratio of the polyethylene glycol-7-stearate to the oleoyl polyoxyethylene glyceride is 1-8: 1.
5. A cannabidiol cream composition according to claim 3, wherein the thickener comprises glyceryl monostearate and dimethicone, and the mass ratio of glyceryl monostearate to dimethicone is 1-5: 1.
6. A cannabidiol cream composition according to claim 1 or 2, wherein the cannabidiol cream composition has a pH of 5 to 6.
7. A cannabidiol cream composition according to claim 1 or 2, wherein the oil phase solvent is a combination of one or more selected from medium chain triglycerides, diethylene glycol monoethyl ether, beeswax, stearic acid and liquid paraffin; and/or the humectant is one or more of glycerol, propylene glycol, amino acid and urea; and/or the antioxidant is one or more of tocopherol, dibutyl hydroxy toluene and butyl hydroxy anisole; and/or the bacteriostatic agent is one or more of phenoxyethanol, methyl paraben and ethyl paraben; and/or the selected pH regulator is one or more of triethanolamine, disodium hydrogen phosphate and sodium hydrogen phosphate; and/or the essential oil is one or more of sweet orange essential oil, lemon essential oil, lavender essential oil and rosemary essential oil.
8. A cannabidiol cream composition according to claim 1 or 2, which exhibits, after storage for at least one month at a temperature of 40 ± 2 ℃ and a relative humidity of 75 ± 5.0%: uniform and fine, without layering, aggregation or precipitation.
9. A method of preparing a cannabidiol cream composition as claimed in any one of claims 1 to 8, comprising the steps of:
step 1: preparing a phase 1-oil phase, mixing an oil phase solvent, an emulsifier, a thickening agent, an antioxidant and a bacteriostatic agent, and heating to 60-80 ℃;
step 2: heating water in the formula to 60-80 ℃ to be used as a phase 2-water phase;
and step 3: preparing a phase 3-drug-containing phase, adding cannabidiol into a humectant, and heating to 60-80 ℃ until the cannabidiol is dissolved and clarified;
and 4, step 4: adding the phase 1-oil phase into the phase 2-water phase under the condition of stirring, and shearing and emulsifying at the temperature of 60-80 ℃ and the rpm of 1000-2000; adding the phase 3-containing medicine phase, and continuously maintaining the temperature of 60-80 ℃ for shearing and emulsification;
and 5: and (3) cooling at 25 +/-5 ℃, adding essential oil, and adjusting the pH value to 5-6 by using a pH regulator to prepare the cannabidiol cream composition.
10. Use of a cannabidiol cream composition as claimed in any one of claims 1 to 8 in a cosmetic or pharmaceutical product for the treatment of eczema, tightening the skin, anti-oxidant repair, delaying ageing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011437715.5A CN112426369A (en) | 2020-12-11 | 2020-12-11 | Cannabidiol cream composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011437715.5A CN112426369A (en) | 2020-12-11 | 2020-12-11 | Cannabidiol cream composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426369A true CN112426369A (en) | 2021-03-02 |
Family
ID=74691527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011437715.5A Pending CN112426369A (en) | 2020-12-11 | 2020-12-11 | Cannabidiol cream composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426369A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112842933A (en) * | 2021-04-02 | 2021-05-28 | 文一丁 | Compound for delaying skin aging and light cream prepared from compound |
-
2020
- 2020-12-11 CN CN202011437715.5A patent/CN112426369A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112842933A (en) * | 2021-04-02 | 2021-05-28 | 文一丁 | Compound for delaying skin aging and light cream prepared from compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4245318A1 (en) | Compound preparation for external use for treating alopecia areata and preparation method therefor | |
| CA2806428C (en) | Formulations containing extracts of echinacea angustifolia and zingiber officinale which are useful in reducing inflammation and peripheral pain | |
| WO1997002041A1 (en) | Transdermal and oral treatment of androgenic alopecia | |
| KR20090010178A (en) | New composition for hair disorders and preparation method thereof | |
| NZ571460A (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| KR102749015B1 (en) | Treatment of skin disorders | |
| CN108186679B (en) | Acne removing composition | |
| EP1716845B1 (en) | Formulation for dermal application | |
| DE69524662T2 (en) | Topical medication with a scarring effect | |
| WO2022178983A1 (en) | External preparation of natural drug, preparation method, and application thereof | |
| KR20020000316A (en) | Alprostadil-containing composition for external application | |
| CN112426369A (en) | Cannabidiol cream composition and preparation method and application thereof | |
| CN113749986A (en) | A kind of shea butter sensitive skin full-effect repair lotion and preparation method and application thereof | |
| EP1399173B1 (en) | Pharmaceutical preparation containing active ingredients extracted from the plants centella asiatica, mahonia aquifolium and viola tricolor | |
| CN102871885B (en) | A kind of hair growth promoter and application thereof | |
| US11344598B2 (en) | Herbal nanoformulations for treating psoriasis and other skin conditions | |
| CA2627021A1 (en) | Combination natural source/local anesthetic/dual component penetration enhancer topical formulation useful for treating pain, itching and/or inflammation of the skin | |
| DE69727507T2 (en) | THERAPEUTIC AND COSMETIC AGENTS, THEIR USE AND PRODUCTION METHOD | |
| Uddin et al. | Antinociceptive effect of methanol extract of Diospyros malabarica (Desr.) Kostel leaves in mice | |
| CN113499356A (en) | Pharmaceutical preparation and application thereof | |
| EP3833371B1 (en) | Formulations containing lipophilic extracts of spicy edible plants useful in controlling pain and inflammation | |
| CN113081933A (en) | Acne-removing composition and preparation method and application thereof | |
| US20190117722A1 (en) | Composition for treating alopecia and methods of making and using the same | |
| IT201900010800A1 (en) | COMPOSITION CONTAINING PRICKLY PEAR EXTRACT IN SERENOA OIL FOR THE MAINTENANCE OF PROSTATE FUNCTIONALITY | |
| JP4101464B2 (en) | Anti-inflammatory ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210302 |